Byambasuren Oyungerel, Stehlik Paulina, Clark Justin, Alcorn Kylie, Glasziou Paul
Bond University, Robina, Queensland, Australia.
Gold Coast University Hospital, Southport, Queensland, Australia.
BMJ Med. 2023 Feb 1;2(1):e000385. doi: 10.1136/bmjmed-2022-000385. eCollection 2023.
To determine the effect of covid-19 vaccination, given before and after acute infection with the SARS-CoV-2 virus, or after a diagnosis of long covid, on the rates and symptoms of long covid.
Systematic review.
PubMed, Embase, and Cochrane covid-19 trials, and Europe PubMed Central (Europe PMC) for preprints, from 1 January 2020 to 3 August 2022.
Trials, cohort studies, and case-control studies reporting on patients with long covid and symptoms of long covid, with vaccination before and after infection with the SARS-CoV-2 virus, or after a diagnosis of long covid. Risk of bias was assessed with the ROBINS-I tool.
1645 articles were screened but no randomised controlled trials were found. 16 observational studies from five countries (USA, UK, France, Italy, and the Netherlands) were identified that reported on 614 392 patients. The most common symptoms of long covid that were studied were fatigue, cough, loss of sense of smell, shortness of breath, loss of taste, headache, muscle ache, difficulty sleeping, difficulty concentrating, worry or anxiety, and memory loss or confusion. 12 studies reported data on vaccination before infection with the SARS-CoV-2 virus, and 10 showed a significant reduction in the incidence of long covid: the odds ratio of developing long covid with one dose of vaccine ranged from 0.22 to 1.03; with two doses, odds ratios were 0.25-1; with three doses, 0.16; and with any dose, 0.48-1.01. Five studies reported on vaccination after infection, with odds ratios of 0.38-0.91. The high heterogeneity between studies precluded any meaningful meta-analysis. The studies failed to adjust for potential confounders, such as other protective behaviours and missing data, thus increasing the risk of bias and decreasing the certainty of evidence to low.
Current studies suggest that covid-19 vaccines might have protective and therapeutic effects on long covid. More robust comparative observational studies and trials are needed, however, to clearly determine the effectiveness of vaccines in preventing and treating long covid.
Open Science Framework https://osf.io/e8jdy.
确定新型冠状病毒2(SARS-CoV-2)病毒急性感染前后或确诊长期新冠后接种新冠疫苗对长期新冠的发生率和症状的影响。
系统评价。
2020年1月1日至2022年8月3日期间,来自PubMed、Embase、Cochrane新冠试验以及欧洲PubMed中心(Europe PMC)的预印本。
关于长期新冠患者及其长期新冠症状的试验、队列研究和病例对照研究,这些研究涉及SARS-CoV-2病毒感染前后或确诊长期新冠后接种疫苗的情况。使用ROBINS-I工具评估偏倚风险。
共筛选了1645篇文章,但未发现随机对照试验。确定了来自五个国家(美国、英国、法国、意大利和荷兰)的16项观察性研究,这些研究报告了614392名患者的情况。所研究的长期新冠最常见症状包括疲劳、咳嗽、嗅觉丧失、呼吸急促、味觉丧失、头痛、肌肉疼痛、睡眠困难、注意力不集中、担忧或焦虑以及记忆力丧失或混乱。12项研究报告了SARS-CoV-病毒感染前接种疫苗的数据,其中10项研究显示长期新冠的发生率显著降低:接种一剂疫苗后患长期新冠的比值比在0.22至1.03之间;接种两剂时,比值比为0.25-1;接种三剂时,比值比为0.16;接种任何剂量时,比值比为0.48-1.01。五项研究报告了感染后接种疫苗的情况,比值比为0.38-0.91。研究之间的高度异质性排除了任何有意义的荟萃分析。这些研究未能对潜在的混杂因素进行调整,如其他保护行为和缺失数据,从而增加了偏倚风险并将证据的确定性降低至低水平。
目前的研究表明,新冠疫苗可能对长期新冠具有保护和治疗作用。然而,需要更有力的比较观察性研究和试验,以明确确定疫苗在预防和治疗长期新冠方面的有效性。
开放科学框架https://osf.io/e8jdy。